Failure of ubiquitin proteasome system: Risk for neurodegenerative diseases

Neurodegenerative Diseases

Volumn 14, Issue 4, 2014, Pages 161-175

  Zheng, Chen ^a   Geetha, Thangiah ^b   Babu, Jeganathan Ramesh ^a  

^a AUBURN UNIVERSITY   (United States)

^b AUBURN UNIVERSITY AT MONTGOMERY   (United States)

Author keywords

Nervous system; Neurodegenerative diseases; Neuronal function; Ubiquitin proteasome system

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; CARRIER PROTEIN; DJ 1 PROTEIN; PARKIN; PINK1 ENZYME; PROTEASOME; PROTEIN P62; PROTEIN SERINE THREONINE KINASE; SUMO PROTEIN; TAU PROTEIN; UBIQUILIN 1; UBIQUITIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; DEGENERATIVE DISEASE; GENE; HUMAN; HUNTINGTON CHOREA; NERVOUS SYSTEM; NONHUMAN; PARKINSON DISEASE; PRION DISEASE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; UCH L1 GENE; ANIMAL; METABOLISM; NEURODEGENERATIVE DISEASES;

ANIMALS; HUMANS; NEURODEGENERATIVE DISEASES; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN;

EID: 84921435917     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000367694     Document Type: Review

References (201)

1. Glickman MH, Ciechanover A: The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2002; 82: 373-428.
2. Pickart CM: Back to the future with ubiquitin. Cell 2004; 116: 181-190.
3. Geetha T, Jiang J, Wooten MW: Lysine 63 polyubiquitination of the nerve growth factor receptor TrkA directs internalization and signaling. Mol cell 2005; 20: 301-312.
4. Deng L, Wang C, Spencer E, Yang L, Braun A, You J, Slaughter C, Pickart C, Chen ZJ: Activation of the IκB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 2000; 103: 351-361.
5. Komander D: The emerging complexity of protein ubiquitination. Biochem Soc Trans 2009; 37: 937-953.
6. Ye Y, Rape M: Building ubiquitin chains: E2 enzymes at work. Nat Rev Mol Cell Biol 2009; 10: 755-764.
7. Nandi D, Tahiliani P, Kumar A, Chandu D: The ubiquitin-proteasome system. J Biosci 2006; 31: 137-155.
8. Chondrogianni N, Gonos ES: Structure and function of the ubiquitin-proteasome system: modulation of components. Prog Mol Biol Transl Sci 2012; 109: 41-74.
9. Layfield R, Cavey JR, Lowe J: Role of ubiquitin-mediated proteolysis in the pathogenesis of neurodegenerative disorders. Ageing Res Rev 2003; 2: 343-356.
10. Bingol B, Schuman EM: Synaptic protein degradation by the ubiquitin proteasome system. Curr Opin Neurobiol 2005; 15: 536-541.
11. Patrick GN: Synapse formation and plasticity: recent insights from the perspective of the ubiquitin proteasome system. Curr Opin Neurobiol 2006; 16: 90-94.
12. Selkoe DJ: Alzheimer's disease is a synaptic failure. Science 2002; 298: 789-791.
13. Hegde AN, Upadhya SC: Role of ubiquitinproteasome-mediated proteolysis in nervous system disease. Biochim Biophys Acta 2011; 1809: 128-140.
14. Selkoe DJ: The molecular pathology of Alzheimer's disease. Neuron 1991; 6: 487-498.
15. Lambon Ralph MA, Patterson K, Graham N, Dawson K, Hodges JR: Homogeneity and heterogeneity in mild cognitive impairment and Alzheimer's disease: a cross-sectional and longitudinal study of 55 cases. Brain 2003; 126: 2350-2362.
16. Artero S, Tierney MC, Touchon J, Ritchie K: Prediction of transition from cognitive impairment to senile dementia: a prospective, longitudinal study. Acta Psychiatr Scand 2003; 107: 390-393.
17. Mattson MP: Pathways towards and away from Alzheimer's disease. Nature 2004; 430: 631-639.
18. Querfurth HW, LaFerla FM: Alzheimer's disease. New Engl J Med 2010; 362: 329-344.
19. Blennow K, de Leon MJ, Zetterberg H: Alzheimer's disease. Lancet 2006; 368: 387-403.
20. Waring SC, Rosenberg RN: Genome-wide association studies in Alzheimer disease. Arch Neurol 2008; 65: 329-334.
21. Chen Y, Bodles AM: Amyloid precursor protein modulates β-catenin degradation. J Neuroinflammation 2007; 4: 29.
22. Minati L, Edginton T, Bruzzone MG, Giaccone G: Current concepts in Alzheimer's disease: a multidisciplinary review. Am J Alzheimer's Dis Other Demen 2009; 24: 95-121.
23. Grillari J, Katinger H, Voglauer R: Aging and the ubiquitinome: traditional and non-traditional functions of ubiquitin in aging cells and tissues. Exp Gerontol 2006; 41: 1067-1079.
24. Oddo S: The ubiquitin-proteasome system in Alzheimer's disease. J Cell Mol Med 2008; 12: 363-373.
25. Aso E, Lomoio S, Lopez-Gonzalez I, Joda L, Carmona M, Fernandez-Yague N, Moreno J, Juves S, Pujol A, Pamplona R, Portero-Otin M, Martin V, Diaz M, Ferrer I: Amyloid generation and dysfunctional immunoproteasome activation with disease progression in animal model of familial Alzheimer's disease. Brain Pathol 2012; 22: 636-653.
26. Gao X, Hu H: Quality control of the proteins associated with neurodegenerative diseases. Acta Biochim Biophys Sin (Shanghai) 2008; 40: 612-618.
27. Liu Y, Hettinger CL, Zhang D, Rezvani K, Wang X, Wang H: The proteasome function reporter GFPu accumulates in young brains of the APPswe/PS1dE9 Alzheimer's disease mouse model. Cell Mol Neurobiol 2014; 34: 315-322.
28. Manavalan A, Mishra M, Feng L, Sze SK, Akatsu H, Heese K: Brain site-specific proteome changes in aging-related dementia. Exp Mol Med 2013; 45: e39.
29. Kikuchi M, Ogishima S, Miyamoto T, Miyashita A, Kuwano R, Nakaya J, Tanaka H: Identification of unstable network modules reveals disease modules associated with the progression of Alzheimer's disease. PLoS One 2013; 8: e76162.
30. Esteras N, Munoz U, Alquezar C, Bartolome F, Bermejo-Pareja F, Martin-Requero A: Altered calmodulin degradation and signaling in non-neuronal cells from Alzheimer's disease patients. Curr Alzheimer Res 2012; 9: 267-277.
31. Benaroudj N, Tarcsa E, Cascio P, Goldberg AL: The unfolding of substrates and ubiquitin-independent protein degradation by proteasomes. Biochimie 2001; 83: 311-318.
32. Lam YA, Pickart CM, Alban A, Landon M, Jamieson C, Ramage R, Mayer RJ, Layfield R: Inhibition of the ubiquitin-proteasome system in Alzheimer's disease. Proc Nat Acad Sci U S A 2000; 97: 9902-9906.
33. Selkoe DJ: Alzheimer's disease: genotypes, phenotypes, and treatments. Science 1997; 275: 630-631.
34. Sisodia SS, St. George-Hyslop PH: γ-Secretase, notch, Aβ and Alzheimer's disease: where do the presenilins fit in? Nat Rev Neurosci 2002; 3: 281-290.
35. Lahiri DK, Maloney B: Beyond the signaling effect role of amyloid-β42 on the processing of APP, and its clinical implications. Exp Neurol 2010; 225: 51-54.
36. Selkoe DJ: Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nat Cell Biol 2004; 6: 1054-1061.
37. Seo H, Isacson O: The hAPP-YAC transgenic model has elevated UPS activity in the frontal cortex similar to Alzheimer's disease and Down's syndrome. J Neurochem 2010; 114: 1819-1826.
38. Qing H, Zhou W, Christensen MA, Sun X, Tong Y, Song W: Degradation of BACE by the ubiquitin-proteasome pathway. FASEB J 2004; 18: 1571-1573.
39. Wang R, Ying Z, Zhao J, Zhang Y, Wang R, Lu H, Deng Y, Song W, Qing H: Lys(203) and Lys(382) are essential for the proteasomal degradation of BACE1. Curr Alzheimer Res 2012; 9: 606-615.
40. Zhang M, Deng Y, Luo Y, Zhang S, Zou H, Cai F, Wada K, Song W: Control of BACE1 degradation and APP processing by ubiquitin carboxyl-terminal hydrolase L1. J Neurochem 2012; 120: 1129-1138.
41. Gregori L, Hainfeld JF, Simon MN, Goldgaber D: Binding of amyloid-β protein to the
42. S proteasome. J Biol Chem 1997; 272: 58-62.
43. Gregori L, Fuchs C, Figueiredo-Pereira ME, Van Nostrand WE, Goldgaber D: Amyloid β-protein inhibits ubiquitin-dependent protein degradation in vitro. J Biol Chem 1995; 270: 19702-19708.
44. Almeida CG, Takahashi RH, Gouras GK: β-Amyloid accumulation impairs multivesicular body sorting by inhibiting the ubiquitinproteasome system. J Neurosci 2006; 26: 4277-4288.
45. Tseng BP, Green KN, Chan JL, Blurton-Jones M, LaFerla FM: Aβ inhibits the proteasome and enhances amyloid and tau accumulation. Neurobiol Aging 2008; 29: 1607-1618.
46. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM: Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004; 43: 321-332.
47. Cecarini V, Bonfili L, Cuccioloni M, Mozzicafreddo M, Rossi G, Keller JN, Angeletti M, Eleuteri AM: Wild-type and mutant amyloid precursor proteins influence downstream effects of proteasome and autophagy inhibition. Biochim Biophys Acta 2013; 1842: 127-134.
48. Lee MJ, Lee JH, Rubinsztein DC: Tau degradation: the ubiquitin-proteasome system versus the autophagy-lysosome system. Prog Neurobiol 2013; 105: 49-59.
49. Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA: Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 1989; 3: 519-526.
50. von Bergen M, Friedhoff P, Biernat J, Heberle J, Mandelkow EM, Mandelkow E: Assembly of protein into Alzheimer paired helical filaments depends on a local sequence motif ( 306 vqivyk 311 ) forming β structure. Proc Natl Acad Sci U S A 2000; 97: 5129-5134.
51. Martin L, Latypova X, Terro F: Post-translational modifications of tau protein: implications for Alzheimer's disease. Neurochem Int 2011; 58: 458-471.
52. Hernandez F, Avila J: Tauopathies. Cell Mol Life Sci 2007; 64: 2219-2233.
53. Wang Y, Garg S, Mandelkow EM, Mandelkow E: Proteolytic processing of tau. Biochem Soc Trans 2010; 38: 955-961.
54. Dolan PJ, Johnson GV: A caspase cleaved form of tau is preferentially degraded through the autophagy pathway. J Biol Chem 2010; 285: 21978-21987.
55. Grune T, Botzen D, Engels M, Voss P, Kaiser B, Jung T, Grimm S, Ermak G, Davies KJ: Tau protein degradation is catalyzed by the ATP/ ubiquitin-independent 20S proteasome under normal cell conditions. Arch Biochem Biophys 2010; 500: 181-188.
56. Yoshida H, Ihara Y: Tau in paired helical filaments is functionally distinct from fetal tau: assembly incompetence of paired helical filament-tau. J Neurochem 1993; 61: 1183-1186.
57. Vogelsberg-Ragaglia V, Schuck T, Trojanowski JQ, Lee VM: Pp2a MRNA expression is quantitatively decreased in Alzheimer's disease hippocampus. Exp Neurol 2001; 168: 402-412.
58. Keck S, Nitsch R, Grune T, Ullrich O: Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease. J Neurochem 2003; 85: 115-122.
59. David DC, Layfield R, Serpell L, Narain Y, Goedert M, Spillantini MG: Proteasomal degradation of tau protein. J Neurochem 2002; 83: 176-185.
60. Cardozo C, Michaud C: Proteasome-mediated degradation of tau proteins occurs independently of the chymotrypsin-like activity by a nonprocessive pathway. Arch Biochem Biophys 2002; 408: 103-110.
61. Cripps D, Thomas SN, Jeng Y, Yang F, Davies P, Yang AJ: Alzheimer disease-specific conformation of hyperphosphorylated paired helical filament-tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation. J Biol Chem 2006; 281: 10825-10838.
62. Keller JN, Hanni KB, Markesbery WR: Impaired proteasome function in Alzheimer's disease. J Neurochem 2000; 75: 436-439.
63. Lopez Salon M, Morelli L, Castano EM, Soto EF, Pasquini JM: Defective ubiquitination of cerebral proteins in Alzheimer's disease. J Neurosci Res 2000; 62: 302-310.
64. Tai HC, Serrano-Pozo A, Hashimoto T, Frosch MP, Spires-Jones TL, Hyman BT: The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. Am J Pathol 2012; 181: 1426-1435.
65. Petrucelli L, Dickson D, Kehoe K, Taylor J, Snyder H, Grover A, De Lucia M, McGowan E, Lewis J, Prihar G, Kim J, Dillmann WH, Browne SE, Hall A, Voellmy R, Tsuboi Y, Dawson TM, Wolozin B, Hardy J, Hutton M: CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum Mol Genet 2004; 13: 703-714.
66. Shimura H, Schwartz D, Gygi SP, Kosik KS: CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival. J Biol Chem 2004; 279: 4869-4876.
67. Dickey CA, Yue M, Lin WL, Dickson DW, Dunmore JH, Lee WC, Zehr C, West G, Cao S, Clark AM, Caldwell GA, Caldwell KA, Eckman C, Patterson C, Hutton M, Petrucelli L: Deletion of the ubiquitin ligase chip leads to the accumulation, but not the aggregation, of both endogenous phospho-and caspase-3-cleaved tau species. J Neurosci 2006; 26: 6985-6996.
68. Layfield R, Alban A, Mayer RJ, Lowe J: The ubiquitin protein catabolic disorders. Neuropathol Appl Neurobiol 2001; 27: 171-179.
69. van Leeuwen FW, de Kleijn DP, van den Hurk HH, Neubauer A, Sonnemans MA, Sluijs JA, Koycu S, Ramdjielal RD, Salehi A, Martens GJ, Grosveld FG, Peter J, Burbach H, Hol EM: Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients. Science 1998; 279: 242-247.
70. van Tijn P, de Vrij FM, Schuurman KG, Dantuma NP, Fischer DF, van Leeuwen FW, Hol EM: Dose-dependent inhibition of proteasome activity by a mutant ubiquitin associated with neurodegenerative disease. J Cell Sci 2007; 120: 1615-1623.
71. Hama E, Shirotani K, Masumoto H, Sekine-Aizawa Y, Aizawa H, Saido TC: Clearance of extracellular and cell-associated amyloid-β peptide through viral expression of neprilysin in primary neurons. J Biochem 2001; 130: 721-726.
72. Choi K, Park J, Lee J, Han EC, Choi C: Mutant ubiquitin attenuates interleukin-1beta-and tumor necrosis factor-alpha-induced pro-inflammatory signaling in human astrocytic cells. PLoS One 2013; 8: e67891.
73. Oddo S, Caccamo A, Smith IF, Green KN, LaFerla FM: A dynamic relationship between intracellular and extracellular pools of Aβ. Am J Pathol 2006; 168: 184-194.
74. Liu Y, Fallon L, Lashuel HA, Liu Z, Lansbury PT Jr: The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell 2002; 111: 209-218.
75. Setsuie R, Wada K: The functions of UCH-L1 and its relation to neurodegenerative diseases. Neurochem Int 2007; 51: 105-111.
76. Gong B, Cao Z, Zheng P, Vitolo OV, Liu S, Staniszewski A, Moolman D, Zhang H, Shelanski M, Arancio O: Ubiquitin hydrolase UCH-L1 rescues β-amyloid-induced decreases in synaptic function and contextual memory. Cell 2006; 126: 775-788.
77. Oddo S, Caccamo A, Tran L, Lambert MP, Glabe CG, Klein WL, LaFerla FM: Temporal profile of amyloid-beta (Aβ) oligomerization in an in vivo model of Alzheimer disease. A link between Aβ and tau pathology. J Biol Chem 2006; 281: 1599-1604.
78. Xue S, Jia J: Genetic association between ubiquitin carboxy-terminal hydrolase-L1 gene S18Y polymorphism and sporadic Alzheimer's disease in a Chinese Han population. Brain Res 2006; 1087: 28-32.
79. Saigoh K, Wang YL, Suh JG, Yamanishi T, Sakai Y, Kiyosawa H, Harada T, Ichihara N, Wakana S, Kikuchi T, Wada K: Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nat Genet 1999; 23: 47-51.
80. Shirotani K, Tsubuki S, Iwata N, Takaki Y, Harigaya W, Maruyama K, Kiryu-Seo S, Kiyama H, Iwata H, Tomita T, Iwatsubo T, Saido TC: Neprilysin degrades both amyloid-β peptides 1-40 and 1-42 most rapidly and efficiently among thiorphan-and phosphoramidon-sensitive endopeptidases. J Biol Chem 2001; 276: 21895-21901.
81. Poon WW, Carlos AJ, Aguilar BL, Berchtold NC, Kawano CK, Zograbyan V, Yaopruke T, Shelanski M, Cotman CW: β-amyloid (Aβ) oligomers impair brain-derived neurotrophic factor retrograde trafficking by down-regulating ubiquitin C-terminal hydrolase, UCH-L1. J Biol Chem 2013; 288: 16937-16948.
82. Bertram L, Hiltunen M, Parkinson M, Ingelsson M, Lange C, Ramasamy K, Mullin K, Menon R, Sampson AJ, Hsiao MY, Elliott KJ, Velicelebi G, Moscarillo T, Hyman BT, Wagner SL, Becker KD, Blacker D, Tanzi RE: Familybased association between Alzheimer's disease and variants in UBQLN1. New Engl J Med 2005; 352: 884-894.
83. Kamboh MI, Minster RL, Feingold E, DeKosky ST: Genetic association of ubiquilin with Alzheimer's disease and related quantitative measures. Mol Psychiatry 2006; 11: 273-279.
84. Slifer MA, Martin ER, Haines JL, Pericak-Vance MA: The ubiquilin 1 gene and Alzheimer's disease. New Engl J Med 2005; 352: 2752-2753, author reply 2752-2753.
85. Golan MP, Melquist S, Safranow K, Styczynska M, Slowik A, Kobrys M, Zekanowski C, Barcikowska M: Analysis of UBQLN1 variants in a Polish Alzheimer's disease patient: control series. Dement Geriatr Cogn Disord 2008; 25: 366-371.
86. Stieren ES, El Ayadi A, Xiao Y, Siller E, Landsverk ML, Oberhauser AF, Barral JM, Boehning D: Ubiquilin-1 is a molecular chaperone for the amyloid precursor protein. J Biol Chem 2011; 286: 35689-35698.
87. Mah AL, Perry G, Smith MA, Monteiro MJ: Identification of ubiquilin, a novel presenilin interactor that increases presenilin protein accumulation. J Cell Biol 2000; 151: 847-862.
88. Viswanathan J, Haapasalo A, Bottcher C, Miettinen R, Kurkinen KM, Lu A, Thomas A, Maynard CJ, Romano D, Hyman BT, Berezovska O, Bertram L, Soininen H, Dantuma NP, Tanzi RE, Hiltunen M: Alzheimer's disease-associated ubiquilin-1 regulates presenilin-1 accumulation and aggresome formation. Traffic 2011; 12: 330-348.
89. Kuusisto E, Salminen A, Alafuzoff I: Early accumulation of p62 in neurofibrillary tangles in Alzheimer's disease: possible role in tangle formation. Neuropathol Appl Neurobiol 2002; 28: 228-237.
90. Shin J: P62 and the sequestosome, a novel mechanism for protein metabolism. Arch Pharm Res 1998; 21: 629-633.
91. Seibenhener Ml, Babu JR, Geetha T, Wong HC, Krishna NR, Wooten MW: Sequestosome 1/p62 is a polyubiquitin chain binding protein involved in ubiquitin proteasome degradation. Mol Cell Biol 2004; 24: 8055-8068.
92. Babu JR, Geetha T, Wooten MW: Sequestosome 1/p62 shuttles polyubiquitinated tau for proteasomal degradation. J Neurochem 2005; 94: 192-203.
93. Nakano T, Nakaso K, Nakashima K, Ohama E: Expression of ubiquitin-binding protein p62 in ubiquitin-immunoreactive intraneuronal inclusions in amyotrophic lateral sclerosis with dementia: analysis of five autopsy cases with broad clinicopathological spectrum. Acta Neuropathol 2004; 107: 359-364.
94. Nakaso K, Yoshimoto Y, Nakano T, Takeshima T, Fukuhara Y, Yasui K, Araga S, Yanagawa T, Ishii T, Nakashima K: Transcriptional activation of p62/A170/ZIP during the formation of the aggregates: possible mechanisms and the role in Lewy body formation in Parkinson's disease. Brain Res 2004; 1012: 42-51.
95. Tanji K, Zhang HX, Mori F, Kakita A, Takahashi H, Wakabayashi K: P62/sequestosome 1 binds to TDP-43 in brains with frontotemporal lobar degeneration with TDP-43 inclusions. J Neurosci Res 2012; 90: 2034-2042.
96. Ramesh Babu J, Lamar Seibenhener M, Peng J, Strom AL, Kemppainen R, Cox N, Zhu H, Wooten MC, Diaz-Meco MT, Moscat J, Wooten MW: Genetic inactivation of p62 leads to accumulation of hyperphosphorylated tau and neurodegeneration. J Neurochem 2008; 106: 107-120.
97. Geetha T, Zheng C, McGregor WC, Douglas White B, Diaz-Meco MT, Moscat J, Babu JR: TRAF6 and p62 inhibit amyloid β-induced neuronal death through p75 neurotrophin receptor. Neurochem Int 2012; 61: 1289-1293.
98. Geetha T, Zheng C, Unroe B, Sycheva M, Kluess H, Babu JR: Polyubiquitination of the neurotrophin receptor p75 directs neuronal cell survival. Biochem Biophys Res Commun 2012; 421: 286-290.
99. Dorval V, Fraser PE: Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein. J Biol Chem 2006; 281: 9919-9924.
100. Takahashi K, Ishida M, Komano H, Takahashi H: SUMO-1 immunoreactivity co-localizes with phospho-tau in APP transgenic mice but not in mutant tau transgenic mice. Neurosci Lett 2008; 441: 90-93.
101. Morishima-Kawashima M, Hasegawa M, Takio K, Suzuki M, Titani K, Ihara Y: Ubiquitin is conjugated with amino-terminally processed tau in paired helical filaments. Neuron 1993; 10: 1151-1160.
102. Gocke CB, Yu H, Kang J: Systematic identification and analysis of mammalian small ubiquitin-like modifier substrates. J Biol Chem 2005; 280: 5004-5012.
103. Zhang YQ, Sarge KD: Sumoylation of amyloid precursor protein negatively regulates Aβ aggregate levels. Biochem Biophys Res Commun 2008; 374: 673-678.
104. Li Y, Wang H, Wang S, Quon D, Liu YW, Cordell B: Positive and negative regulation of APP amyloidogenesis by sumoylation. Proc Nat Acad Sci U S A 2003; 100: 259-264.
105. Dorval V, Mazzella MJ, Mathews PM, Hay RT, Fraser PE: Modulation of Aβ generation by small ubiquitin-like modifiers does not require conjugation to target proteins. Biochem J 2007; 404: 309-316.
106. Song S, Kim SY, Hong YM, Jo DG, Lee JY, Shim SM, Chung CW, Seo SJ, Yoo YJ, Koh JY, Lee MC, Yates AJ, Ichijo H, Jung YK: Essential role of E2-25K/Hip-2 in mediating amyloid-β neurotoxicity. Mol Cell 2003; 12: 553-563.
107. Song S, Lee H, Kam TI, Tai ML, Lee JY, Noh JY, Shim SM, Seo SJ, Kong YY, Nakagawa T, Chung CW, Choi DY, Oubrahim H, Jung YK: E2-25K/Hip-2 regulates caspase-12 in ER stress-mediated Aβ neurotoxicity. J Cell Biol 2008; 182: 675-684.
108. Jin JK, Choi JK, Wasco W, Buxbaum JD, Kozlowski PB, Carp RI, Kim YS, Choi EK: Expression of calsenilin in neurons and astrocytes in the Alzheimer's disease brain. Neuroreport 2005; 16: 451-455.
109. Jo DG, Lee JY, Hong YM, Song S, Mook-Jung I, Koh JY, Jung YK: Induction of proapoptotic calsenilin/DREAM/KChIP3 in Alzheimer's disease and cultured neurons after amyloid-β exposure. J Neurochem 2004; 88: 604-611.
110. Jang C, Choi JK, Kim E, Park ES, Wasco W, Buxbaum JD, Kim YS, Choi EK: Calsenilin is degraded by the ubiquitin-proteasome pathway. Biochem Biophys Res Commun 2011; 405: 180-185.
111. Walker FO: Huntington's disease. Lancet 2007; 369: 218-228.
112. Myers RH: Huntington's disease genetics. NeuroRx 2004; 1: 255-262.
113. Huntington's Disease Collaborative Research Group: A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72: 971-983.
114. Duyao M, Ambrose C, Myers R, Novelletto A, Persichetti F, Frontali M, Folstein S, Ross C, Franz M, Abbott M, et al: Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat Genet 1993; 4: 387-392.
115. Andrew SE, Goldberg YP, Kremer B, Telenius H, Theilmann J, Adam S, Starr E, Squitieri F, Lin B, Kalchman MA, et al: The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat Genet 1993; 4: 398-403.
116. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, Aronin N: Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997; 277: 1990-1993.
117. Borrell-Pages M, Zala D, Humbert S, Saudou F: Huntington's disease: from huntingtin function and dysfunction to therapeutic strategies. Cell Mol Life Sci 2006; 63: 2642-2660.
118. Sanchez I, Mahlke C, Yuan J: Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 2003; 421: 373-379.
119. Sieradzan KA, Mechan AO, Jones L, Wanker EE, Nukina N, Mann DM: Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein. Exp Neurol 1999; 156: 92-99.
120. Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, Scherzinger E, Wanker EE, Mangiarini L, Bates GP: Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997; 90: 537-548.
121. Jana NR, Zemskov EA, Wang G, Nukina N: Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome C release. Hum Mol Genet 2001; 10: 1049-1059.
122. Kalchman MA, Graham RK, Xia G, Koide HB, Hodgson JG, Graham KC, Goldberg YP, Gietz RD, Pickart CM, Hayden MR: Huntingtin is ubiquitinated and interacts with a specific ubiquitin-conjugating enzyme. J Biol Chem 1996; 271: 19385-19394.
123. Thompson LM, Aiken CT, Kaltenbach LS, Agrawal N, Illes K, Khoshnan A, Martinez-Vincente M, Arrasate M, O'Rourke JG, Khashwji H, Lukacsovich T, Zhu YZ, Lau AL, Massey A, Hayden MR, Zeitlin SO, Finkbeiner S, Green KN, LaFerla FM, Bates G, Huang L, Patterson PH, Lo DC, Cuervo AM, Marsh JL, Steffan JS: IKK phosphorylates huntingtin and targets it for degradation by the proteasome and lysosome. J Cell Biol 2009; 187: 1083-1099.
124. Steffan JS, Agrawal N, Pallos J, Rockabrand E, Trotman LC, Slepko N, Illes K, Lukacsovich T, Zhu YZ, Cattaneo E, Pandolfi PP, Thompson LM, Marsh JL: SUMO modification of huntingtin and Huntington's disease pathology. Science 2004; 304: 100-104.
125. Lunkes A, Lindenberg KS, Ben-Haiem L, Weber C, Devys D, Landwehrmeyer GB, Mandel JL, Trottier Y: Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. Mol Cell 2002; 10: 259-269.
126. Holmberg CI, Staniszewski KE, Mensah KN, Matouschek A, Morimoto RI: Inefficient degradation of truncated polyglutamine proteins by the proteasome. EMBO J 2004; 23: 4307-4318.
127. Venkatraman P, Wetzel R, Tanaka M, Nukina N, Goldberg AL: Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins. Mol Cell 2004; 14: 95-104.
128. Bhutani N, Venkatraman P, Goldberg AL: Puromycin-sensitive aminopeptidase is the major peptidase responsible for digesting polyglutamine sequences released by proteasomes during protein degradation. EMBO J 2007; 26: 1385-1396.
129. Rousseau E, Kojima R, Hoffner G, Djian P, Bertolotti A: Misfolding of proteins with a polyglutamine expansion is facilitated by proteasomal chaperones. J Biol Chem 2009; 284: 1917-1929.
130. Michalik A, Van Broeckhoven C: Proteasome degrades soluble expanded polyglutamine completely and efficiently. Neurobiol Dis 2004; 16: 202-211.
131. Bennett EJ, Bence NF, Jayakumar R, Kopito RR: Global impairment of the ubiquitinproteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation. Mol Cell 2005; 17: 351-365.
132. Pandey UB, Nie Z, Batlevi Y, McCray BA, Ritson GP, Nedelsky NB, Schwartz SL, Di-Prospero NA, Knight MA, Schuldiner O, Padmanabhan R, Hild M, Berry DL, Garza D, Hubbert CC, Yao TP, Baehrecke EH, Taylor JP: HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 2007; 447: 859-863.
133. Martinez-Vicente M, Cuervo AM: Autophagy and neurodegeneration: when the cleaning crew goes on strike. Lancet Neurol 2007; 6: 352-361.
134. Wichmann T, DeLong MR: Functional neuroanatomy of the basal ganglia in Parkinson's disease. Adv Neurol 2003; 91: 9-18.
135. Branco DM, Arduino DM, Esteves AR, Silva DF, Cardoso SM, Oliveira CR: Cross-talk between mitochondria and proteasome in Parkinson's disease pathogenesis. Front Aging Neurosci 2010; 2: 17.
136. Winklhofer KF, Haass C: Mitochondrial dysfunction in Parkinson's disease. Biochim Biophys Acta 2010; 1802: 29-44.
137. Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S, Ali Z, Del Turco D, Bentivoglio AR, Healy DG, Albanese A, Nussbaum R, Gonzalez-Maldonado R, Deller T, Salvi S, Cortelli P, Gilks WP, Latchman DS, Harvey RJ, Dallapiccola B, Auburger G, Wood NW: Hereditary earlyonset Parkinson's disease caused by mutations in PINK1. Science 2004; 304: 1158-1160.
138. Cookson MR: The biochemistry of Parkinson's disease. Ann Rev Biochem 2005; 74: 29-52.
139. Zhang NY, Tang Z, Liu CW: α-Synuclein protofibrils inhibit 26 S proteasome-mediated protein degradation: understanding the cytotoxicity of protein protofibrils in neurodegenerative disease pathogenesis. J Biol Chem 2008; 283: 20288-20298.
140. Chen L, Thiruchelvam MJ, Madura K, Richfield EK: Proteasome dysfunction in aged human α-synuclein transgenic mice. Neurobiol Dis 2006; 23: 120-126.
141. Tofaris GK, Layfield R, Spillantini MG: α-Synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome. FEBS Lett 2001; 509: 22-26.
142. Tanaka Y, Engelender S, Igarashi S, Rao RK, Wanner T, Tanzi RE, Sawa A, L Dawson V, Dawson TM, Ross CA: Inducible expression of mutant α-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum Mol Genet 2001; 10: 919-926.
143. Stefanis L, Larsen KE, Rideout HJ, Sulzer D, Greene LA: Expression of A53T mutant but not wild-type α-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J Neurosci 2001; 21: 9549-9560.
144. Tofaris GK, Razzaq A, Ghetti B, Lilley KS, Spillantini MG: Ubiquitination of α-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J Biol Chem 2003; 278: 44405-44411.
145. Snyder H, Mensah K, Theisler C, Lee J, Matouschek A, Wolozin B: Aggregated and monomeric α-synuclein bind to the S6' proteasomal protein and inhibit proteasomal function. J Biol Chem 2003; 278: 11753-11759.
146. Lindersson E, Beedholm R, Hojrup P, Moos T, Gai W, Hendil KB, Jensen PH: Proteasomal inhibition by α-synuclein filaments and oligomers. J Biol Chem 2004; 279: 12924-12934.
147. Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E, Harta G, Brownstein MJ, Jonnalagada S, Chernova T, Dehejia A, Lavedan C, Gasser T, Steinbach PJ, Wilkinson KD, Polymeropoulos MH: The ubiquitin pathway in Parkinson's disease. Nature 1998; 395: 451-452.
148. Hegde AN, Inokuchi K, Pei W, Casadio A, Ghirardi M, Chain DG, Martin KC, Kandel ER, Schwartz JH: Ubiquitin C-terminal hydrolase is an immediate-early gene essential for long-term facilitation in aplysia. Cell 1997; 89: 115-126.
149. Wilkinson KD: Regulation of ubiquitin-dependent processes by deubiquitinating enzymes. FASEB J 1997; 11: 1245-1256.
150. Ragland M, Hutter C, Zabetian C, Edwards K: Association between the ubiquitin carboxyl-terminal esterase L1 gene (UCHL1) S18Y variant and Parkinson's disease: a huge review and meta-analysis. Am J Epidemiol 2009; 170: 1344-1357.
151. Kyratzi E, Pavlaki M, Stefanis L: The S18Y polymorphic variant of UCH-L1 confers an antioxidant function to neuronal cells. Hum Mol Genet 2008; 17: 2160-2171.
152. Bekris LM, Mata IF, Zabetian CP: The genetics of Parkinson disease. J Geriatr Psychiatry Neurol 2010; 23: 228-242.
153. Nagakubo D, Taira T, Kitaura H, Ikeda M, Tamai K, Iguchi-Ariga SM, Ariga H: DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with Ras. Biochem Biophys Res Commun 1997; 231: 509-513.
154. Shang H, Lang D, Jean-Marc B, Kaelin-Lang A: Localization of DJ-1 mRNA in the mouse brain. Neurosci Lett 2004; 367: 273-277.
155. Kotaria N, Hinz U, Zechel S, von Bohlen Und Halbach O: Localization of DJ-1 protein in the murine brain. Cell Tissue Res 2005; 322: 503-507.
156. Bandopadhyay R, Kingsbury AE, Cookson MR, Reid AR, Evans IM, Hope AD, Pittman AM, Lashley T, Canet-Aviles R, Miller DW, McLendon C, Strand C, Leonard AJ, Abou-Sleiman PM, Healy DG, Ariga H, Wood NW, de Silva R, Revesz T, Hardy JA, Lees AJ: The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease. Brain 2004; 127: 420-430.
157. van Horssen J, Drexhage JA, Flor T, Gerritsen W, van der Valk P, de Vries HE: NRF2 and DJ1 are consistently upregulated in inflammatory multiple sclerosis lesions. Free Radic Biol Med 2010; 49: 1283-1289.
158. Nural H, He P, Beach T, Sue L, Xia W, Shen Y: Dissembled DJ-1 high molecular weight complex in cortex mitochondria from Parkinson's disease patients. Mol Neurodegener 2009; 4: 23.
159. Cookson MR, Bandmann O: Parkinson's disease: insights from pathways. Hum Mol Genet 2010; 19: R21-R27.
160. Andres-Mateos E, Perier C, Zhang L, Blanchard-Fillion B, Greco TM, Thomas B, Ko HS, Sasaki M, Ischiropoulos H, Przedborski S, Dawson TM, Dawson VL: DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proc Natl Acad Sci U S A 2007; 104: 14807-14812.
161. Kim RH, Smith PD, Aleyasin H, Hayley S, Mount MP, Pownall S, Wakeham A, You-Ten AJ, Kalia SK, Horne P, Westaway D, Lozano AM, Anisman H, Park DS, Mak TW: Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc Natl Acad Sci U S A 2005; 102: 5215-5220.
162. Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, Dekker MC, Squitieri F, Ibanez P, Joosse M, van Dongen JW, Vanacore N, van Swieten JC, Brice A, Meco G, van Duijn CM, Oostra BA, Heutink P: Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003; 299: 256-259.
163. Xiong H, Wang D, Chen L, Choo YS, Ma H, Tang C, Xia K, Jiang W, Ronai Z, Zhuang X, Zhang Z: Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation. J Clin Invest 2009; 119: 650-660.
164. Thomas KJ, McCoy MK, Blackinton J, Beilina A, van der Brug M, Sandebring A, Miller D, Maric D, Cedazo-Minguez A, Cookson MR: DJ-1 acts in parallel to the PINK1/parkin pathway to control mitochondrial function and autophagy. Hum Mol Genet 2011; 20: 40-50.
165. Shinbo Y, Niki T, Taira T, Ooe H, Takahashi-Niki K, Maita C, Seino C, Iguchi-Ariga SM, Ariga H: Proper SUMO-1 conjugation is essential to DJ-1 to exert its full activities. Cell Death Differ 2006; 13: 96-108.
166. Heeman B, Van den Haute C, Aelvoet SA, Valsecchi F, Rodenburg RJ, Reumers V, Debyser Z, Callewaert G, Koopman WJ, Willems PH, Baekelandt V: Depletion of PINK1 affects mitochondrial metabolism, calcium homeostasis and energy maintenance. J Cell Sci 2011; 124: 1115-1125.
167. Blackinton JG, Anvret A, Beilina A, Olson L, Cookson MR, Galter D: Expression of PINK1 mRNA in human and rodent brain and in Parkinson's disease. Brain Res 2007; 1184: 10-16.
168. Clements CM, McNally RS, Conti BJ, Mak TW, Ting JP: DJ-1, a cancer-and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator NRF2. Proc Natl Acad Sci U S A 2006; 103: 15091-15096.
169. Kitada T, Pisani A, Porter DR, Yamaguchi H, Tscherter A, Martella G, Bonsi P, Zhang C, Pothos EN, Shen J: Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice. Proc Natl Acad Sci U S A 2007; 104: 11441-11446.
170. Kitada T, Tong Y, Gautier CA, Shen J: Absence of nigral degeneration in aged parkin/ DJ-1/PINK1 triple knockout mice. J Neurochem 2009; 111: 696-702.
171. Liu W, Vives-Bauza C, Acin-Perez R, Yamamoto A, Tan Y, Li Y, Magrane J, Stavarache MA, Shaffer S, Chang S, Kaplitt MG, Huang XY, Beal MF, Manfredi G, Li C: PINK1 defect causes mitochondrial dysfunction, proteasomal deficit and α-synuclein aggregation in cell culture models of Parkinson's disease. PLoS One 2009; 4: e4597.
172. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N: Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392: 605-608.
173. Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, Shimizu N, Iwai K, Chiba T, Tanaka K, Suzuki T: Familial Parkinson disease gene product, parkin, is an ubiquitin-protein ligase. Nat Genet 2000; 25: 302-305.
174. Hattori N, Matsumine H, Asakawa S, Kitada T, Yoshino H, Elibol B, Brookes AJ, Yamamura Y, Kobayashi T, Wang M, Yoritaka A, Minoshima S, Shimizu N, Mizuno Y: Point mutations (Thr240Arg and Gln311Stop) in the parkin gene. Biochem Biophys Res Commun 1998; 249: 754-758.
175. Song YJ, Halliday GM, Holton JL, Lashley T, O'Sullivan SS, McCann H, Lees AJ, Ozawa T, Williams DR, Lockhart PJ, Revesz TR: Degeneration in different parkinsonian syndromes relates to astrocyte type and astrocyte protein expression. J Neuropathol Exp Neurol 2009; 68: 1073-1083.
176. Shimura H, Hattori N, Kubo S, Yoshikawa M, Kitada T, Matsumine H, Asakawa S, Minoshima S, Yamamura Y, Shimizu N, Mizuno Y: Immunohistochemical and subcellular localization of parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients. Ann Neurol 1999; 45: 668-672.
177. Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, Schneider R, Mizuno Y, Kosik KS, Selkoe DJ: Ubiquitination of a new form of α-synuclein by parkin from human brain: implications for Parkinson's disease. Science 2001; 293: 263-269.
178. Lim KL, Dawson VL, Dawson TM: Parkinmediated lysine 63-linked polyubiquitination: a link to protein inclusions formation in Parkinson's and other conformational diseases? Neurobiol Aging 2006; 27: 524-529.
179. Imai Y, Soda M, Takahashi R: Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J Biol Chem 2000; 275: 35661-35664.
180. Imai Y, Soda M, Inoue H, Hattori N, Mizuno Y, Takahashi R: An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of parkin. Cell 2001; 105: 891-902.
181. Tsai YC, Fishman PS, Thakor NV, Oyler GA: Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function. J Biol Chem 2003; 278: 22044-22055.
182. Winborn BJ, Travis SM, Todi SV, Scaglione KM, Xu P, Williams AJ, Cohen RE, Peng J, Paulson HL: The deubiquitinating enzyme ataxin-3, a polyglutamine disease protein, edits Lys63 linkages in mixed linkage ubiquitin chains. J Biol Chem 2008; 283: 26436-26443.
183. Todi SV, Winborn BJ, Scaglione KM, Blount JR, Travis SM, Paulson HL: Ubiquitination directly enhances activity of the deubiquitinating enzyme ataxin-3. EMBO J 2009; 28: 372-382.
184. Olzmann JA, Li L, Chin LS: Aggresome formation and neurodegenerative diseases: therapeutic implications. Curr Med Chem 2008; 15: 47-60.
185. Muftuoglu M, Elibol B, Dalmizrak O, Ercan A, Kulaksiz G, Ogus H, Dalkara T, Ozer N: Mitochondrial complex I and IV activities in leukocytes from patients with parkin mutations. Mov Disord 2004; 19: 544-548.
186. Bedford L, Hay D, Devoy A, Paine S, Powe DG, Seth R, Gray T, Topham I, Fone K, Rezvani N, Mee M, Soane T, Layfield R, Sheppard PW, Ebendal T, Usoskin D, Lowe J, Mayer RJ: Depletion of 26S proteasomes in mouse brain neurons causes neurodegeneration and Lewy-like inclusions resembling human pale bodies. J Neurosci 2008; 28: 8189-8198.
187. Wahl C, Kautzmann S, Krebiehl G, Strauss K, Woitalla D, Muller T, Bauer P, Riess O, Kruger R: A comprehensive genetic study of the proteasomal subunit S6 ATPase in German Parkinson's disease patients. J Neural Transm 2008; 115: 1141-1148.
188. Deng HX, Hentati A, Tainer JA, Iqbal Z, Cayabyab A, Hung WY, Getzoff ED, Hu P, Herzfeldt B, Roos RP, et al: Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase. Science 1993; 261: 1047-1051.
189. Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Vande Velde C, Bouchard JP, Lacomblez L, Pochigaeva K, Salachas F, Pradat PF, Camu W, Meininger V, Dupre N, Rouleau GA: TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet 2008; 40: 572-574.
190. Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, Russ C, Davis A, Gilchrist J, Kasarskis EJ, Munsat T, Valdmanis P, Rouleau GA, Hosler BA, Cortelli P, de Jong PJ, Yoshinaga Y, Haines JL, Pericak-Vance MA, Yan J, Ticozzi N, Siddique T, McKenna-Yasek D, Sapp PC, Horvitz HR, Landers JE, Brown RH Jr: Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009; 323: 1205-1208.
191. Vance C, Rogelj B, Hortobagyi T, De Vos KJ, Nishimura AL, Sreedharan J, Hu X, Smith B, Ruddy D, Wright P, Ganesalingam J, Williams KL, Tripathi V, Al-Saraj S, Al-Chalabi A, Leigh PN, Blair IP, Nicholson G, de Belleroche J, Gallo JM, Miller CC, Shaw CE: Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009; 323: 1208-1211.
192. Deng HX, Chen W, Hong ST, Boycott KM, Gorrie GH, Siddique N, Yang Y, Fecto F, Shi Y, Zhai H, Jiang H, Hirano M, Rampersaud E, Jansen GH, Donkervoort S, Bigio EH, Brooks BR, Ajroud K, Sufit RL, Haines JL, Mugnaini E, Pericak-Vance MA, Siddique T: Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 2011; 477: 211-215.
193. Johnston JA, Dalton MJ, Gurney ME, Kopito RR: Formation of high molecular weight complexes of mutant Cu,Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2000; 97: 12571-12576.
194. Hoffman EK, Wilcox HM, Scott RW, Siman R: Proteasome inhibition enhances the stability of mouse Cu/Zn superoxide dismutase with mutations linked to familial amyotrophic lateral sclerosis. J Neurol Sci 1996; 139: 15-20.
195. Niwa J, Ishigaki S, Hishikawa N, Yamamoto M, Doyu M, Murata S, Tanaka K, Taniguchi N, Sobue G: Dorfin ubiquitylates mutant SOD1 and prevents mutant SOD1-mediated neurotoxicity. J Biol Chem 2002; 277: 36793-36798.
196. Matsumoto S, Goto S, Kusaka H, Imai T, Murakami N, Hashizume Y, Okazaki H, Hirano A: Ubiquitin-positive inclusion in anterior horn cells in subgroups of motor neuron diseases: a comparative study of adultonset amyotrophic lateral sclerosis, juvenile amyotrophic lateral sclerosis and Werdnig-Hoffmann disease. J Neurol Sci 1993; 115: 208-213.
197. Kristiansen M, Deriziotis P, Dimcheff DE, Jackson GS, Ovaa H, Naumann H, Clarke AR, van Leeuwen FW, Menendez-Benito V, Dantuma NP, Portis JL, Collinge J, Tabrizi SJ: Disease-associated prion protein oligomers inhibit the 26S proteasome. Mol Cell 2007; 26: 175-188.
198. Ma J, Lindquist S: Wild-type PRP and a mutant associated with prion disease are subject to retrograde transport and proteasome degradation. Proc Natl Acad Sci U S A 2001; 98: 14955-14960.
199. Homma T, Ishibashi D, Nakagaki T, Satoh K, Sano K, Atarashi R, Nishida N: Increased expression of p62/SQSTM1 in prion diseases and its association with pathogenic prion protein. Sci Rep 2014; 4: 4504.
200. Heiseke A, Aguib Y, Riemer C, Baier M, Schatzl HM: Lithium induces clearance of protease-resistant prion protein in prioninfected cells by induction of autophagy. J Neurochem 2009; 109: 25-34.
201. Aguib Y, Heiseke A, Gilch S, Riemer C, Baier M, Schatzl HM, Ertmer A: Autophagy induction by trehalose counteracts cellular prion infection. Autophagy 2009; 5: 361-369